The story behind Gecko Biomedical’s biocompatible sealant starts in the summer of 2009, when Boston Children’s Hospital‘s chief of cardiac surgery reached out to Jeffrey Karp about a problem he was experiencing in the operating room. Dr. Pedro del Nido told Karp, a professor of medicine at Harvard and the director of the Laboratory for […]
Surgical
Medtech stories we missed this week: Oct. 20, 2017
From InspireMD’s distribution deal to RenalGuard touting a new study, here are seven medtech stories we missed this week but thought were still worth a mention. 1. InspireMD inks Chile distribution deal InspireMD announced in an Oct. 12 press release that it has signed a distribution deal with CorpMedical Chile to distribute the MGuard Prime […]
The 11 most innovative medical devices of 2017
The nominees for the best medical technology of 2017 were recently announced for the 11th Annual Prix Galien USA Awards. The Galien Foundation, the host of the awards, hands out the Prix Galien Award annually to examples of outstanding biomedical and technology product achievement designed to improve human condition. Before candidates can qualify for the […]
MiMedx closes Stability Biologics sale
MiMedx (NSDQ:MDXG) said this week that it completed the divestiture of its subsidiary, Stability Biologics, back to the former stockholders of Stability, Inc. The deal, which closed on Sept. 30, included a promissory note issued by Stability Biologics for $3.5 million in favor of MiMedx. “When we signed the definitive agreement for the divestiture, we communicated […]
Grifols wins FDA nod for liquid formulation of replacement therapy for rare genetic disorder
Grifols (NSDQ:GRFS) said today that it won FDA approval for a liquid formulation of its alpha-1 antitrypsin, Prolastin-C Liquid, as a replacement therapy to treat alpha-1 antitrypsin deficiency. Prior to this approval, the company only offered Prolastin-C in a lyophilized format. The new formulation requires less preparation time and volume for infusion, according to Barcelona-based […]
Medtech stories we missed this week: Sept. 15, 2017
From Acera Surgical and Telos Medical’s partnership to Xtant Medical’s 510(k) clearance, here are seven medtech stories we missed this week but thought were still worth a mention. 1. Acera Surgical partners with Telos Medical for Restrata wound matrix trial Telos Partners announced in a Sept. 14 press release that Acera Surgical has chosen Telos to […]
Medtech stories we missed this week: September 8, 2017
From BrainScope’s pediatric traumatic brain injury assessment device to EOS Imaging releasing new surgery planning software, here are seven medtech stories we missed this week but thought were still worth a mention. 1. BrainScope to develop pediatric traumatic brain injury assessment device BrainScope announced in a Sept. 7 press release that it will immediately start creating […]
Lumicell launches breast cancer, prostate cancer trials with Lum image-guided system
Lumicell said today that it is launching clinical studies in breast cancer and prostate cancer with its Lum image-guided cancer surgery system. The breast cancer trial is a pivotal study following an initial training period with surgeons, the Wellesley, Mass.-based company reported, and the prostate cancer study is a first for Lumicell and its technology. […]
Medtech stories we missed this week: Aug. 25, 2017
From InspireMD’s Swiss distribution deal to CoreLink’s stackable guide wire launch, here are seven medtech stories we missed this week but thought were still worth a mention. 1. InspireMD announces Swiss distribution deal InspireMD announced in an Aug. 25 press release that it has signed an agreement with 1a Medical to distribute the CGuard EPS (Embolic […]
Omeros closes $68m public offering
Biopharma company Omeros (NSDQ:OMER) said that it closed a $68.3 million underwritten public offering last week, selling 3 million shares of its common stock at $22.75 apiece. After deducting fees and other expenses, Omeros said it is slated to reel in $63.6 million from the offering. The company plans to use its newly-acquired funds to […]